A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 917 participants.
Also called NCT04093752
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 917 participants
- Sponsor
- Registry
-
NCT04093752
-
- Other papers using this trial's data
- Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, China, India, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04093752. Randomized; no masking; primary purpose treatment. Start 2019-12-09 (actual); primary completion 2021-11-01 (actual). Results posted on 2023-01-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04093752- Content hash
64f26170d877f55f7b13796d6324f2ae84467613e8dcfe83ac8f9d1f5e67884c